ABSTRACT
As antimicrobial therapy for pneumonia has not been well established in Japan, this study was designed to obtain a more definitive standard for antimicrobial treatment of this condition. Two hundred and thirty-one emergency patients admitted to Kyorin University Hospital between January 1998 and December 2000 were retrospectively analyzed in respect to their age, underlying disease, causative organism, and primary treatment with antimicrobial agent. Furthermore, the severity and prognosis were analyzed for those patients who had not responded to initial treatment with antimicrobial agents. The majority of the patients were elderly (over 65 years old; mean overall age 66.7 +/- 15.2 years) and had severe pneumonia; underlying diseases were recognized at a high rate in patients with severe pneumonia (P < 0.05) and in those classified as elderly (P < 0.0001). The most common underlying conditions in elderly patients were respiratory, cardiovascular (P < 0.01), and cerebrovascular (P < 0.05) diseases. The most common causative organisms were Haemophilus influenzae, Staphylococcus aureus, Streptococcus pneumoniae, and Mycoplasma pneumoniae. In patients with severe pneumonia, S. aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa were identified as the most common causative organisms. Complications associated with antimicrobial treatment were observed in those patients with K. pneumoniae isolates who also had severe pneumonia and were frequently treated with penicillin. Furthermore, increased mortality rates were observed in patients not responding well to the initial treatment with antimicrobial agents. Thus, the selection of appropriate initial antimicrobial agents is an important factor affecting the prognosis of patients with community-acquired pneumonia.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Emergency Service, Hospital/standards , Outcome Assessment, Health Care , Pneumonia, Bacterial/drug therapy , Pneumonia, Bacterial/epidemiology , Aged , Chlamydophila Infections/drug therapy , Chlamydophila Infections/epidemiology , Chlamydophila Infections/etiology , Chlamydophila Infections/microbiology , Chlamydophila Infections/pathology , Chlamydophila pneumoniae , Community-Acquired Infections/drug therapy , Community-Acquired Infections/epidemiology , Community-Acquired Infections/etiology , Community-Acquired Infections/microbiology , Community-Acquired Infections/pathology , Emergency Service, Hospital/statistics & numerical data , Female , Hospitals, University , Humans , Japan/epidemiology , Male , Medical Records , Mycoplasma pneumoniae , Pneumonia, Bacterial/etiology , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/pathology , Pneumonia, Mycoplasma/drug therapy , Pneumonia, Mycoplasma/epidemiology , Pneumonia, Mycoplasma/etiology , Pneumonia, Mycoplasma/microbiology , Pneumonia, Mycoplasma/pathology , Practice Guidelines as Topic , Retrospective Studies , Severity of Illness IndexABSTRACT
Adult Still's disease is an important differential diagnosis of pyretic disease and it does not necessarily appear to be a distinct disease entity. The etiology of adult Still's disease is not yet known. However, it has been considered that adult Still's disease may be triggered by certain infections, such as the Coxsackie, parvo B19, rubella, mumps, Epstein-Barr, and cytomegalo virus, as well as mycoplasma, toxoplasma, and so on. Recently, we experienced a patient with adult Still's disease with an increased Chlamydia pneumoniae antibody titer. The titer decreased slowly after the beginning of steroid therapy, associated with improvement of clinical symptoms. In this report we mention the relationship between the pathogenesis of adult Still's disease and a high titer of Chlamydia pneumoniae antibody.
Subject(s)
Antibodies, Bacterial/blood , Chlamydophila pneumoniae/immunology , Still's Disease, Adult-Onset/microbiology , Adult , Chaperonin 60/immunology , Humans , Interleukin-6/blood , Male , Receptors, Antigen, T-Cell, gamma-delta/analysis , Still's Disease, Adult-Onset/immunology , T-Lymphocytes/immunologyABSTRACT
A 75-year-old male suffered from interstitial pneumonia in December 2000 and treated with predonisolone. The treatment was effective, and the dosage of predonisolone had been gradually tapered. In January 2001, when the dosage was 30 mg/day, he complained of cough and yellowish sputum. The chest X-ray and CT revealed bilateral infiltrations with cavities. He was treated with cefozopram and fluconazole. However, there were no improvements. The sputa of the 2nd, 3rd, 6th and 8th hospital days showed the presence of gram-positive branched rods, which were identified as Nocardia farcinica. Therefore, the treatment was changed to sulfamethoxazole-trimethoprim. During the treatment, serum concentration of sulfamethoxazole was repeatedly measured, and kept over 60 microgram/ml. He was swiftly recovered after the start of sulfamethoxazole-trimethoprim. This case was supposed to be the seventh one of N. farcinica pneumonia in Japan, and the measurement of the concentration of sulfamethoxazole was useful to determine its dosage.
